New hope for HIV patients with kaposi sarcoma: cheaper drug may work just as well
NCT ID NCT05411237
First seen Dec 12, 2025 · Last updated May 22, 2026 · Updated 22 times
Summary
This study tests whether a common chemotherapy drug, paclitaxel, works as well as a more expensive one, pegylated liposomal doxorubicin, for treating Kaposi sarcoma in people with HIV. About 130 participants in sub-Saharan Africa will receive one of the two drugs every three weeks for six cycles. The goal is to see if both drugs are similarly effective at stopping the cancer from growing, while also comparing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.